Approval

Spruce Power Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Matters

Retrieved on: 
월요일, 5월 6, 2024
Utilities, Construction & Property, Sustainability, Environment, Alternative Energy, Energy, Green Technology, Residential Building & Real Estate, MAKE, XL, Stipulation, Service award, Mediator, Notice, District court, ALL, Hearing, Negotiation, Clerk, READ, Party, Approval, Documentation, Complaint, FLEET, Settlement, Calendar, YOU, Derivative, Vii, ALSO, Prejudice, Reform, COMMON, Plaintiff, Acquisition, Fee, Episcopal conference, Judgement, Insurance

THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF STOCKHOLDER DERIVATIVE LITIGATION AND CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS.

Key Points: 
  • THIS NOTICE RELATES TO A PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE OF STOCKHOLDER DERIVATIVE LITIGATION AND CONTAINS IMPORTANT INFORMATION REGARDING YOUR RIGHTS.
  • IF THE COURT APPROVES THE SETTLEMENT OF THE DERIVATIVE MATTERS, CURRENT SPRUCE POWER STOCKHOLDERS WILL BE FOREVER BARRED FROM CONTESTING THE APPROVAL OF THE PROPOSED SETTLEMENT AND DISMISSAL WITH PREJUDICE, AND FROM PURSUING RELEASED CLAIMS.
  • ), pending in the Court (the “Massachusetts Action”);
    the existence of a similar derivative action captioned In re Spruce Power Holding Corp. S’holder Derivative Litig., Case No.
  • This Notice is solely to advise you of the proposed Settlement of the Derivative Matters and of your rights in connection with the proposed Settlement.

EQS-News: NOTICE OF CALL OF THE ORDINARY SHAREHOLDERS' MEETING

Retrieved on: 
금요일, 5월 3, 2024
Annual general meeting, Prejudice, News, Communication, Proxy, Approval, Exercise, Documentation, Shareholder, Record, Legislation, Bank statement, Credit, Legislature, Person, Security (finance)

The share capital is equal to Euro 368,981.06 divided into 2,592,984 ordinary shares without indication of par value; each share entitles the holder to one vote in the Company's ordinary and extraordinary shareholders' meetings.

Key Points: 
  • The share capital is equal to Euro 368,981.06 divided into 2,592,984 ordinary shares without indication of par value; each share entitles the holder to one vote in the Company's ordinary and extraordinary shareholders' meetings.
  • To this end, the appropriate proxy form is available on the Company's website at the address https://rigsave.com/ , in the "Investor Relations" section, "Shareholders' Meeting".
  • Shareholders are entitled to attend the shareholders' meeting and exercise their right to vote also by audio-video-conference.
  • Shareholders are invited to connect via audio-video-conference as early as necessary to ensure the holding of the Shareholders' Meeting.

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

Retrieved on: 
수요일, 5월 1, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Mortality, FDA, Risk, ICS, Death, Weight loss, Growth, Gastrointestinal tract, Rash, TSLP, Formoterol, Biopharmaceutical, AstraZeneca, LABA, Inflammation, Salbutamol, Skin, Tezepelumab, Approval, EGPA, AMG, Allergy, Polyp (medicine), Bronchitis, Chronic obstructive pulmonary disease, Patient, Eosinophilic, Sinusitis, Rheumatology, Heart, Atmosphere, Fatigue, Immunology, Budesonide, Lung, Chronic pain, Asthma, COPD, Gastroenterology, Emphysema, Disease, Science, Conditional sentence, Dermatology, Pharmaceutical industry

In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.

Key Points: 
  • In addition, we are also collaborating with AstraZeneca on AMG104/AZD8630, an inhaled anti-TSLP compound currently in development for asthma.
  • Respiratory & Immunology, part of BioPharmaceuticals, is one of AstraZeneca’s main disease areas and is a key growth driver for the Company.
  • With common pathways and underlying disease drivers across respiratory and immunology, AstraZeneca is following the science from chronic lung diseases to immunology-driven disease areas.
  • AstraZeneca’s ambition in Respiratory & Immunology is to achieve disease modification and durable remission for millions of patients worldwide.

DoubleDown Interactive Announces Results of 2024 Annual General Meeting

Retrieved on: 
금요일, 3월 29, 2024
Approval

SEATTLE, March 29, 2024 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, announced today that at its annual general meeting of shareholders held on March 29, 2024 at 11:00 a.m., Korea Standard Time (March 28, 2024 at 10:00 p.m., U.S. Eastern Time) in Seoul, Korea, the following actions were taken by the shareholders of record as of December 29, 2023 on the proposed resolutions:

Key Points: 
  • SEATTLE, March 29, 2024 (GLOBE NEWSWIRE) -- DoubleDown Interactive Co., Ltd. (NASDAQ: DDI) (“DoubleDown” or the “Company”), a leading developer and publisher of digital games on mobile and web-based platforms, announced today that at its annual general meeting of shareholders held on March 29, 2024 at 11:00 a.m., Korea Standard Time (March 28, 2024 at 10:00 p.m., U.S. Eastern Time) in Seoul, Korea, the following actions were taken by the shareholders of record as of December 29, 2023 on the proposed resolutions:
    Approval of the 16th financial statements for the fiscal year ended December 31, 2023;
    Approval of the aggregate remuneration limit of KRW5,000,000,000 for independent directors and executive officers for the fiscal year ending December 31, 2024; and
    Approval of the amendment to the Regulations on Executive Retirement Payment.

Sword Group: NOTICE OF CONVOCATION TO THE SHAREHOLDERS FOR THE ANNUAL ORDINARY GENERAL MEETING OF THE COMPANY

Retrieved on: 
목요일, 3월 28, 2024
Remuneration, Approval, Proxy, Mass meeting, Policy, Bank statement, Confidentiality, Security (finance)

Shareholders have the right to ask questions regarding items on the agenda of the General Meeting.

Key Points: 
  • Shareholders have the right to ask questions regarding items on the agenda of the General Meeting.
  • The Ordinary General Meeting will validly deliberate on the agenda items if at least 25% of the issued share capital is present or represented.
  • The Extraordinary General Meeting will validly deliberate on the agenda items if at least 50% of the issued share capital is represented.
  • This notice shall serve as a notice of convocation unless any modifications are made to the agenda following requests for the inclusion of resolution proposals submitted by shareholders.

Notice - RAYMOND POMROY, File No. 2024-3

Retrieved on: 
금요일, 3월 8, 2024
Approval, Settlement, Commission, Order, Vexatious litigation, Tribunal

TORONTO, March 8, 2024 /CNW/ - Following a hearing held today, the Tribunal issued an Order in the above- named matter approving the Settlement Agreement reached between Staff of the Commission and Raymond Pomroy.

Key Points: 
  • TORONTO, March 8, 2024 /CNW/ - Following a hearing held today, the Tribunal issued an Order in the above- named matter approving the Settlement Agreement reached between Staff of the Commission and Raymond Pomroy.
  • A copy of the Order dated March 8, 2024, Settlement Agreement dated February 26, 2024 and Oral Reasons for Approval of a Settlement dated March 8, 2024 are available at capitalmarketstribunal.ca

BIRD - Israel-U.S. Binational Industrial R&D Foundation to invest $9.6 million in 10 new projects: The approved projects, with an overall budget of $24.5 million, involve innovations in the areas of Agrotech, Biotechnology, Electronics, Energy, Foodtech,

Retrieved on: 
수요일, 1월 31, 2024
Misgav, MD, BIRD Foundation, Commerce, BIRD, Planner, Associate, Partnership, Yokneam Illit, Mayo Clinic, History, TEL, Carbon, Splenic infarction, Lod, Intelligence, Sheba Medical Center, Patient, Ministry, Mondelez International, NIST, Approval, Virtual reality, Anopheles, Agriculture, Anopheles stephensi, Parity, Rehovot, ATCC, Hope, Malaria, Pharmaceutical industry

In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.

Key Points: 
  • In addition to the grants from BIRD, the projects will access private-sector funding, boosting the total investment in all projects to $24.5 million.
  • The BIRD Foundation promotes collaborations between U.S. and Israeli companies in various technological sectors for joint product development.
  • In addition to providing conditional grants of up to $1.5 million, the Foundation assists by working with companies to identify potential strategic partners and facilitate introductions.
  • The ten projects approved by the Board of Governors are in addition to the over 1000 projects that the BIRD Foundation has approved for funding during its 46-year history.

Notice - NICHOLAS AGAR and PAUL UNGERMAN, File No. 2024-1

Retrieved on: 
월요일, 1월 29, 2024
Tribunal, Commission, Order, Settlement, Vexatious litigation, Approval

TORONTO, Jan. 29, 2024 /CNW/ - The Tribunal issued an Order in the above-named matter approving the Settlement Agreement reached between Staff of the Commission, Nicholas Agar and Paul Ungerman in the above-named matter.

Key Points: 
  • TORONTO, Jan. 29, 2024 /CNW/ - The Tribunal issued an Order in the above-named matter approving the Settlement Agreement reached between Staff of the Commission, Nicholas Agar and Paul Ungerman in the above-named matter.
  • A copy of the Order dated January 26, 2024, Settlement Agreement dated January 10, 2024 and Reasons for Approval of a Settlement dated January 26, 2024 are available at capitalmarketstribunal.ca

AIRSUPRA® (albuterol/budesonide) now available as the first and only FDA-approved anti-inflammatory rescue option for asthma

Retrieved on: 
월요일, 1월 22, 2024
FDA, Health, Managed Care, Clinical Trials, Pharmaceutical, Biotechnology, Ageing, Budesonide, Potassium, Allergy, Swelling, Mouth, Patient, Cataract, Pneumonia, Rash, Approval, Wheeze, Multimedia, Cough, Face, Kidney, Hypokalemia, ICS, International, Fungal infection, Catherine Disher, Medicine, Risk, Immunology, Global Initiative for Asthma, Water, Periodic breathing, Disease, Inflammation, Tongue, OCS, Common, Glaucoma, Red, Treatment, Itch, Chest pain, Salbutamol, Headache, Cardiovascular disease, US6, Pharmaceutical industry

In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.

Key Points: 
  • In MANDALA, AIRSUPRA was superior to albuterol in reducing the risk of severe asthma exacerbations in patients with moderate to severe asthma.
  • In DENALI, AIRSUPRA had a similar onset of bronchodilation compared to albuterol in patients with mild to moderate asthma.2
    The approach to treating asthma symptoms with rescue has changed.
  • The 2023 Global Initiative for Asthma (GINA) report supports a rescue approach that treats both symptoms and inflammation together.
  • Now, with AIRSUPRA available we can provide patients, especially those on maintenance therapy, another rescue option for managing their breakthrough symptoms.

Red White & Bloom Brands Transitions to International Cannabis Company Through Closing of Aleafia Transaction

Retrieved on: 
월요일, 1월 15, 2024
ECC, Hand, Corporation, Sale, Practitioner, Monitor, Transaction, CFO, Basalt, Marketing, RWB, Physician, Divvy, Approval, Acquisition, Patient, Health, OTC, Rationalization, CCAA, Security (finance)

TORONTO, Jan. 15, 2024 (GLOBE NEWSWIRE) -- Red White & Bloom Brands Inc. (CSE: RWB and OTC: RWBYF) (“RWB”) is pleased to announce that, in connection with the proceedings of Aleafia Health Inc. (“Aleafia Health”) and certain of its subsidiaries (collectively, the “Aleafia Group”) under the Companies’ Creditors Arrangement Act (the “CCAA Proceedings”), the parties have successfully closed the previously announced sale transaction (the “Transaction”), as further described below.

Key Points: 
  • “The accretive nature of the Transaction has been evident to RWB management since the inception of the relationship with the Aleafia group of companies.
  • With the closing behind us, the combined, dedicated RWB and Aleafia teams are focused on delivering accessible synergies focused within sales, production, procurement, and marketing."
  • One of Canada’s largest virtual medical cannabis clinics that provides quality cannabis products to patient subscribers in a convenient and low-cost setting.
  • An established portfolio of loyal cannabis brands in both adult use (recreational) and medical channels.